Member Info for AquaeSulis01

Market Cap today £58M
Net Proceeds from Settlement £71M
Annual Revenue £1.6M
Net Cash £6M
Monthly Cash Burn £0.1M

FILL YOUR BOOTS THIS IS AS CLOSE AS YOU GET TO A NO BRAINER

Yes hopefully Clio. Toyin. as you are a genuine sufferer who has benefitted from Axis, might be worth you posting the link on the UK Psoriasis Forum
https://www.psoriasis-association.org.uk/forums/

Great initiative better than letting all the stock date expire

https://axisbiotix.com/pages/60-day-skin-challenge

A more balanced view of the RNS is that the Geology suggests there should be economic deposits of Nickel Sulphide which probably resides in one or more deep pockets but they haven't found those pockets yet and will need a well funded partner to carry out the extensive drilling to locate them

mol the Apr 20 is a reference to 20% off discount not the year 2020. Both CholBiomeVH and CholBiomeCH are brand new formulas
https://optibiotix.online/collections/cholbiome-range/products/cholbiomech-probiotic-supplement-30-tablets
https://optibiotix.online/collections/cholbiome-range/products/cholbiomevh-probiotic-supplement-30-capsules

bel, it is not your views that other posters have objected to and are looking to censor but the way you have expressed them in libellous terms directed at SA. It is one thing to say that you personally do not believe the reasons given for missed targets which is your opinion and acceptable but quite another to accuse someone of lying which over steps the mark.
With regards Pre-registrations for AxisBiotix-Ps, which I presume is what you meant to reference in terms of "growing at an alarming rate", I explained in a previous post how this was likely very true at the time as an expression of interest with no commitment to buy is open to potential manipulation by traders and their mates in an attempt to spike the share price, however, if you recall the Company was not allowed to use expressions of interest as a guide to future sales because of the unreliability of those figures. Also, the £1.2M forecast revenue (not profit) was also considered a reasonable forecast based on the proposed partnerships at the time by the NOMAD, so no evidence on your part to support that it definitely wasn't on the table.

Good spot elrico, in addition to the newly formulated wellbiome being available in the online shop, there are now 4 versions of cholbiome

https://optibiotix.online/collections/wellbiome/products/wellbiome

Toyin/Bel, point of clarification do you mean Pre-registrations for AxisBiotix-Ps or subscription rates because they are two very different things? The former were an expression of interest with no commitment to buy which was always open to potential manipulation by traders and their mates in an attempt to spike the share price, whilst the latter is a commitment to buy on a recurring basis with discounts offered as an incentive.

My response bigpunt wasn't just addressed at your speculation , it was also in response to elrico's speculating comment that "Moreover, IMHO, a price had likely been agreed upon, hence the placing, which blows a hole in points 1, 2 & 3.". The RNS makes it perfectly clear that the placing was primarily to enable Business as Usual to continue for another 12 months enabling the right-to -the-wire accounts to be published without a going concern qualification. A SEPARATE FUND RAISE VIA DEBT OR EQUITY WILL BE NEEDED FOR ANY ACQUISITION SHOULD THAT PROCEED it could not be clearer

ffs why don't people just properly read the Placing and Rex Retail offer RNS?
"The primary purpose of the Fundraising is to fund the continued roll-out of Axis-PS into Europe and Rest of World, accelerate development and commercialisation of acne treatment, build out in-house formulation and scientific capabilities, as well as general working capital. " So yes needed to keep the lights on as evidenced by the further comment "Should Shareholder approval not be obtained at the General Meeting, neither the Placing nor the Retail Offer will proceed and the Company would not receive the funds relating to the Placing or the Retail Offer which would limit the amount of working capital available to it. Neither the Placing nor the Retail Offer has been underwritten. The Company would need to consider the options available to it in terms of alternative sources of funding. It may be that such sources would not be available or not available on favourable terms. Accordingly, if alternative sources of funding could not be secured, the Company expects that it would not have sufficient cash for its current level of activities beyond early in the second quarter of calendar year 2023."
Secondary reason for the fund raise was "The Fundraise will also provide a strengthened balance sheet for negotiations with potential acquisition targets." That said, the fact that only £162K gross out of a hoped for £1M Rex Retail offer was raised, the balance sheet was not strengthened as much as the company would have liked.
Finally, "The proposed target is profitable and the Company sees a number of synergies to improve this. However, there is no certainty of timing or execution as the Company would need to agree additional funding using debt and/or equity and any acquisition would be conditional on satisfactory diligence." so more funds will have to be found if the acquisition goes ahead

bel, the Company has elected to follow a strategy of accretive acquisition and multi-national partner deals with an eye on bigger margins and profits in the long term rather than playing a short term game with high advertising spend which may or may not payoff.
So far there has been no news on strategy progress and hence the share price languishes whilst investors wait to see whether SA proceeds with or walks away from a proposed acquisition that will act as a catalyst to a multi partner deal.
We still await news on the acne consumer study originally forecast for end 2022, and any news on Croda revenues and their scale which based on the Q&A, I trust will be no later than third quarter 2023. We are where we are which isn't currently where we want to be but speculating on what/ifs serves no constructive purpose whatsoever

At least one Institution sees the value potential here
"ProBiotix Health Plc – A company established by OptiBiotix
Health Plc, a B share pool existing investment, to develop
probiotics to tackle cardiovascular disease and other lifestyle
conditions which are affecting growing numbers of people
across the world.
£777k"
https://senecavct.co.uk/wp-content/uploads/2023/04/Seneca-VCT-Annual-Report-April-2023-Signed.pdf

Good timing for sweetbiotix
"One of the key drivers for Kelso's investment in THG, as announced on 31 January 2023 (the "January Announcement"), was around the significant intrinsic value of the nutrition business (referred to going forward as "MyProtein"), which in part, we referred to in the January Announcement is caused 'by the shift in consumption away from chocolate and sugar to health and nutrition'.



We note yesterday's public statement by the Healthy Markets Initiative, a group of 26 global institutional investors with assets under management of over $5.3 trillion as outlined by Alistair Gray's article in the Food and Beverage section of the Financial Times and on the BBC website on 19 April 2023. These investors are engaging with the world's largest food manufacturers to promote changes in their strategy away from an over-reliance on sales of less healthy products. The Financial Times article refers to potential 'systemic risk' to companies that are over reliant on sales of these unhealthy foods. This article encapsulates exactly what Kelso referred to as the 'chocolate and sugar problem' and the need for these companies to diversify their revenues into healthier products for long term success. In our view, this strategic shift is akin to the major oil companies diversifying into renewable energy and highlights the huge relevance and underlying value of THG Nutrition.



Kelso has identified 12 global food and beverage companies1 that it believes could be deemed overly focussed on sales of chocolate or high sugar content products. The average market capitalisation of the 10 listed companies identified is $96.1 billion with an average revenue of $30.5 billion, the remaining 2 businesses being private. Kelso calculates that the average enterprise value to sales of these companies is 4.3x. THG has announced this week the sales of its nutrition business, including MyProtein, as being c$800m for the year ended 31 December 2022.
1Nestle, Coca Cola, Pepsi, Mondelez, Mars*, Hershey, Ferrero*, General Mills, Lotus Bakeries, Monster, Kraft Heinz, Keirig Dr Pepper *Denotes private"
https://www.londonstockexchange.com/news-article/KLSO/update-on-thg-investment-and-placing/15925580

It would appear so Andrew coupled with the fact that putting PBX on the AQSE means the shares are pretty illiquid and difficult for most to trade. I have no doubt at the 18 mth stage (Sep 23) PBX will be moved to AIM and the sp will rise considerably as the EOY results will have been published leaving no room for doubt as to how under valued the asset is The value of Opti's holding will rise accordingly and SOH will start to sell down no doubt to fund the JV with Firminech for the stevia based aweetbiotix products.

Skid, 2021 was an unique year as the covid situation meant just about every company overstocked to guard against supply chain issues and hence inflated sales growth artificially. Consequently, I have lost count of the number of RNS's I have read where first half 2022 sales have been depressed because customers have subsequently rundown stocks and delayed orders. What SO H has attempted to show with PBX is that despite the early part of H2 being history lower orders the recovery since then has rebounded so quickly that with a quarter of 2022 remaining orders had already exceeded the whole of 2021 which is quite remarkable in the circumstances, so fully understand why a direct comparison was not used for H1 sales.

skid,
As regards PBX as at the 28th Sep 2022 RNS this was stated "Confirmed orders to end of August of £1.12m, higher than sales for FY 2021 (£1.1m)" which isn't a view it is a FACT

The future of the business is and always has been the second generation products, the issue is it is about damn time they arrived in the present.
It is also extremely disappointing that a Trading and Commercial Update providing second half financials for both PBX and Opti have yet to be published as I fully expect the former to show continued revenue growth and the latter to show a much improved position from H1 which should act as a catalyst to sp recovery

bel, the sp has moved within the same range over the last 3 months. The last time the price started to move u sharply (around 23rd Feb) you had this to say "Brilliant to see such confidence in the buying today. Not saying our company is leaky, but clearly someone knows something more than we do. Might be someone from the other party of course. In stocks with high liquidity its masked but here it stands out a country mile.
Not a time to take profits I think."
Well obviously no leak then as the sp fell back again pre RNS (I suspect because peeps realised there was no new news likely before the predictable results), and if I remember correctly, you were once again one of the sellers when it hit 23p, and it doesn't take much in the way of volume to move this stock.

So on the face of it you were wrong about positive leaks in Feb, wrong about negative leaks leading up to the results RNS, and I suspect wrong once ah=gain about new positive leaks.

Stuart may well deserve criticism for several missed deadlines and targets, but insinuating the company is a leaky ship is totally unjustified.

ADM increasing their interest in the microbiome modulator space
https://www.businesswire.com/news/home/20230406005144/en/ADM-and-Brightseed-Launch-Global-Partnership-To-Decode-How-The-Gut-Microbiome-Bioactives-Impact-Human-Health

more helpful link lol

https://www.telegraph.co.uk/business/2023/04/07/chinas-green-leap-forward-is-a-nightmare-for-saudi-arabia-a/